Brief: Servier And Black Diamond Therapeutics Announce Global Licensing Agreement For BDTX-4933, A Targeted Oncology Therapy
19/03/2025 11:09
March 19 (Reuters) - Black Diamond Therapeutics Inc BDTX.O: SERVIER AND BLACK DIAMOND THERAPEUTICS ANNOUNCE GLOBAL LICENSING AGREEMENT FOR BDTX-4933, A TARGETED ONCOLOGY THERAPY BLACK DIAMOND THERAPEUTICS - TO RECEIVE $70 MILLION UPFRONT, UP TO $710 MILLION IN MILESTONES Source text: ID:nGNX5KLFVG Further company coverage: BDTX.O ((Reuters.Briefs@thomsonreuters.com))
Recent news on Black Diamond Therapeutics
See all newsBlack Diamond Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Black Diamond Therapeutics Q2 net loss narrows year over year
Black Diamond Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Black Diamond Therapeutics Q4 net loss narrows, full-year profit turns positive
U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox